Search results
Patients with sporadic breast cancer should be adequately informed about the estimated risks and benefits of undergoing a contralateral prophylactic mastectomy. The CBCRisk may be useful for the counseling of these patients, but it requires validation in larger and prospective cohorts.
20 lip 2005 · Contralateral breast cancer (CBC) is the most common second primary cancer in patients diagnosed with breast cancer. 1 Patients with a history of breast cancer have an increased risk of developing a second primary breast cancer (PBC), with an annual risk of 0.5% to 1% or a cumulative lifetime risk of 2% to 15%. 2 Because breast cancer is the ...
Full Text. Introduction. Contralateral prophylactic mastectomy (CPM) has been evaluated as a strategy for reducing the risk of contralateral breast cancer (CBC) in patients with sporadic breast cancer (BC) (ie, no mutations in the main genes associated with hereditary breast cancer, and no strong family history) 1.
1 gru 2020 · Introducción. La mastectomía contralateral profiláctica (MCP) reduce el riesgo de cáncer contralateral en al menos un 90%. Además, las portadoras de mutación BRCA tienen mayor riesgo de recurrencia ipsilateral y de un segundo tumor primario.
A cancer in the contralateral breast in a woman with a previous or synchronous breast cancer is typically considered to be an independent primary tumor. Emerging evidence suggests that in a small subset of these cases the second tumor represents a metastasis.
9 sty 2023 · Germline BRCA1, BRCA2, and CHEK2 PV carriers with breast cancer were at a significantly elevated risk of CBC, whereas only the PALB2 PV carriers with estrogen receptor–negative breast cancer had elevated risks. By contrast, ATM PV carriers did not have significantly increased CBC risks.
2 cze 2022 · This study seeks to determine the risk of SPCs, including contralateral breast cancer (CBCa), in women with early-stage invasive lobular carcinoma (ILC). Methods: The study population consisted of women with BCa diagnosis between 2000-2018 within the NCI Surveillance, Epidemiology, and End Results (SEER v 3.2.9) registry and between 2000-2021 ...
